Aventis, Mylan Debate Validity Of Prostate Cancer Treatment In Patent Appeal

Mealey's (May 11, 2018, 1:09 PM EDT) -- WASHINGTON, D.C. — Mylan Laboratories Ltd. on April 24 defended a final written decision of the Patent Trial and Appeal Board, which deemed obvious various claims of an Aventis Pharma S.A....
To view the full article, register now.